[1]秦 莉,邱秀霞.肝病降脂颗粒对非酒精性脂肪肝患者肝脏生化及血脂水平的影响[J].医学信息,2022,35(21):65-68.[doi:10.3969/j.issn.1006-1959.2022.21.014]
　QIN Li,QIU Xiu-xia.Effect of Ganbing Jiangzhi Granules on Liver Biochemistry and Blood Lipid Levels in Patients with Nonalcoholic Fatty Liver Disease[J].Journal of Medical Information,2022,35(21):65-68.[doi:10.3969/j.issn.1006-1959.2022.21.014]
点击复制

肝病降脂颗粒对非酒精性脂肪肝患者肝脏生化及血脂水平的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年21期
页码:
65-68
栏目:
论著
出版日期:
2022-11-01

文章信息/Info

Title:
Effect of Ganbing Jiangzhi Granules on Liver Biochemistry and Blood Lipid Levels in Patients with Nonalcoholic Fatty Liver Disease
文章编号:
1006-1959（2022）21-0065-04
作者:
秦 莉; 邱秀霞
（天津市第一医院中医科1，消化科2，天津 300232）
Author(s):
QIN Li; QIU Xiu-xia
(Department of Traditional Chinese Medicine1,Department of Gastroenterology2,Tianjin First Hospital,Tianjin 300232,China)
关键词:
非酒精性脂肪肝; 肝病降脂颗粒; 肝脏生化指标; 血脂水平
Keywords:
Nonalcoholic fatty liver disease; Ganbing Jiangzhi granules; Liver reserve function; Blood lipid level
分类号:
R575.5
DOI:
10.3969/j.issn.1006-1959.2022.21.014
文献标志码:
A
摘要:
目的 研究肝病降脂颗粒对非酒精性脂肪肝（NAFLD）患者肝脏生化及血脂水平的影响。方法 选取2020年3月-2021年3月我院收治的70例NAFLD患者，通过随机数字表法分为对照组与观察组，各35例。对照组给予多烯磷脂酰胆碱治疗，观察组在对照组基础上给予肝病降脂颗粒治疗，比较两组临床疗效、中医证候积分、体质量（BMI）、肝脏生化指标[谷丙转氨酶（ALT）、谷草转氨酶（AST）、谷氨酰转肽酶（GGT）]、血脂水平[总胆固醇（TC）、甘油三酯（TG）]。结果 观察组治疗总有效率为88.57%，高于对照组的80.00%，差异有统计学意义（P＜0.05）。两组治疗后中医证候积分及BMI低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）。两组治疗后ALT、AST、GGT水平低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）。两组治疗后TC、TG水平低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）。结论 肝病降脂颗粒在NAFLD治疗中具有确切疗效，可缓解临床症状，减轻患者体重，改善肝脏生化指标，恢复血脂紊乱。
Abstract:
Objective To study the effect of Ganbing Jiangzhi granules on liver biochemistry and blood lipid levels in patients with nonalcoholic fatty liver disease (NAFLD).Methods Seventy patients with NAFLD admitted to our hospital from March 2020 to March 2021 were selected and divided into control group and observation group by random number table method, with 35 cases in each group. The control group was treated with polyene phosphatidylcholine, and the observation group was treated with Ganbing Jiangzhi granules on the basis of the control group. The clinical efficacy, TCM syndrome score, body mass (BMI), liver biochemical indexes [alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT)] and blood lipid levels [total cholesterol (TC), triglyceride (TG)] were compared between the two groups.Results The total effective rate of treatment in the observation group was 88.57%, which was higher than 80.00% in the control group, and the difference was statistically significant (P<0.05). After treatment, the scores of TCM syndromes and BMI in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group, the differences were statistically significant (P<0.05). After treatment, the levels of ALT, AST and GGT in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group, the differences were statistically significant (P<0.05). The levels of TC and TG in the two groups after treatment were lower than those before treatment, and those in the observation group was lower than those in the control group, the differences were statistically significant (P<0.05).Conclusion Ganbing Jiangzhi granules has definite curative effect in the treatment of NAFLD, which can relieve clinical symptoms, reduce body weight, improve liver biochemical indexes and restore dyslipidemia.

参考文献/References:

[1]Shi T,Wu L,Ma W,et al.Nonalcoholic Fatty Liver Disease: Pathogenesis and Treatment in Traditional Chinese Medicine and Western Medicine[J].Evidence-Based Complementary and Alternative Medicine,2020,15(6):1-16.[2]谢俊峰,胡云淑.硫普罗宁联合多烯磷脂酰胆碱治疗非酒精性脂肪性肝炎的临床研究[J].河北医药,2017,39(15):2263-2266.[3]高鹰,周颖.胆宁片联合多烯磷脂酰胆碱胶囊治疗非酒精性脂肪肝的疗效观察[J].现代药物与临床,2017,32(3):464-467.[4]陈靓,黄强,刘三海,等.五苓散联合多烯磷脂酰胆碱对非酒精性脂肪肝病的临床观察[J].中华中医药学刊,2020,38(6):190-193.[5]程亚伟,王婷,蔡媛媛,等.鹧鸪降脂颗粒对非酒精性脂肪肝临床疗效[J].中成药,2019,41(12):3077-3079.[6]尹抗抗,王柏果,徐琦,等.降脂理肝汤对非酒精性脂肪肝大鼠肠黏膜屏障的影响[J].湖南中医药大学学报,2019,39(9):1089-1093.[7]中国中西医结合学会消化系统疾病专业委员会.非酒精性脂肪性肝病中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2017,25(11):805-811.[8]朱成慧,吕冠华,孙希良,等.降脂护肝方联合瑞舒伐他汀钙片治疗痰瘀互结型非酒精性脂肪肝的临床观察[J].海南医学院学报,2019,25(1):12-15.[9]姚贺之,孙明月,柴露露,等.基于网络药理学研究舒肝降脂胶囊治疗非酒精性脂肪性肝病的作用机制[J].中成药,2018,40(11):2389-2393.[10]王晓芳,路振宇,党殿杰.自拟化瘀降脂汤联合西药洛伐他汀治疗非酒精性脂肪肝(痰湿内阻证)疗效观察[J].四川中医,2018,36(10):88-90.[11]耿秀丽,王华民,孙海龙,等.降脂片对非酒精性脂肪肝大鼠血脂和血清中ALT、AST、γ-GT水平的影响[J].中国药师,2018,21(9):1528-1530.[12]胡振斌,柳琳琳,陈永洪,等.疏肝降脂颗粒治疗非酒精性脂肪性肝炎临床观察[J].中西医结合肝病杂志,2018,28(4):208-210.[13]丁麟,蔡新吉,王巍,等.降脂化瘀汤联合水飞蓟宾葡甲胺片对痰瘀互结型非酒精性脂肪肝患者血清ALT、AST、GGT水平及血脂代谢的影响[J].中国中西医结合消化杂志,2018,26(7):561-565.[14]周烨威,王继海,郑井平,等.活血降脂方治疗非酒精性脂肪肝的CT定量疗效评价[J].现代中西医结合杂志,2018,27(9):975-977.[15]胡振斌,陈永洪,王秀峰,等.疏肝降脂颗粒对非酒精性脂肪性肝病患者血清瘦素及脂联素水平的影响[J].中西医结合肝病杂志,2018,28(1):23-24,62.[16]李春颖.柴苓降脂汤治疗痰湿郁阻型脂肪肝合并高脂血症的有效性及安全性[J].临床医学,2017,37(7):115-117.[17]薛建华,吴香香,傅益飞,等.清肝降脂方联合异甘草酸镁治疗非酒精性脂肪肝临床观察[J].中医药信息,2019,36(3):95-98.[18]卞晓岚,郑岚.降脂利肝颗粒联合辛伐他汀治疗非酒精性脂肪肝的临床疗效观察[J].中国药物警戒,2017,14(2):71-74.[19]Sun L,Wang Q,Liu M,et al.Albumin binding function is a novel biomarker for early liver damage and disease progression in non-alcoholic fatty liver disease[J].Endocrine,2020,69(1):294-302.[20]Li HS,Hu YY.Intestinal Microecology: An Important Target for Chinese Medicine Treatment of Non-alcoholic Fatty Liver Disease[J].Chinese Journal of Integrative Medicine,2020,26:723-728.[21]Korniichuk I,Khukhlina O,Vivsyannuk V,et al.Features of Glucose Homeostasis and Blood Lipid Spectrum in Patients with Nonalcoholic Fatty Liver Dis ease Depending on the Obesity Degree[J].Lviv Clinical Bulletin,2019,1(25):27-33.[22]刘洋,徐娇雅,杨丽丽,等.基于权重配方法的降脂颗粒改善非酒精性脂肪性肝病的有效成分配伍优化研究[J].上海中医药杂志,2021,55(3):65-73.[23]赵梓铭,武俊紫,姚政,等.决明子蒽醌苷通过降低Toll样受体4和核因子-κB的表达对非酒精性脂肪肝病大鼠的影响[J].中国临床药理学杂志,2019,35(22):2863-2867.

相似文献/References:

[1]谢雨萌,毛乾国.非酒精性脂肪肝患者中医体质及相关证型研究[J].医学信息,2018,31(07):46.[doi:10.3969/j.issn.1006-1959.2018.07.016]
　XIE Yu-meng,MAO Qian-guo.Study on TCM Constitution and Correlative Syndromes of Nonalcoholic Fatty Liver Patients[J].Journal of Medical Information,2018,31(21):46.[doi:10.3969/j.issn.1006-1959.2018.07.016]
[2]刘 瑜,王 星,代 萌,等.2型糖尿病合并非酒精性脂肪肝的危险因素研究[J].医学信息,2018,31(23):108.[doi:10.3969/j.issn.1006-1959.2018.23.029]
　LIU Yu,WANG Xing,DAI Meng,et al.Study on Risk Factors of Type 2 Diabetes Mellitus with Non-alcoholic Fatty liver Disease[J].Journal of Medical Information,2018,31(21):108.[doi:10.3969/j.issn.1006-1959.2018.23.029]
[3]于 淙,欧阳天佐,周 培.吡格列酮治疗非酒精性脂肪肝有效性及安全性的Meta分析[J].医学信息,2020,33(13):60.[doi:10.3969/j.issn.1006-1959.2020.13.017]
　YU Cong,OUYANG Tian-zuo,ZHOU Pei.Meta-analysis of the Efficacy and Safety of Pioglitazone in the Treatment of Non-alcoholic Fatty Liver[J].Journal of Medical Information,2020,33(21):60.[doi:10.3969/j.issn.1006-1959.2020.13.017]
[4]黄丽玲,吴春城,梁惠卿,等.血清标志物壳多糖酶3样蛋白1评价肝纤维化的研究[J].医学信息,2021,34(10):32.[doi:10.3969/j.issn.1006-1959.2021.10.009]
　HUANG Li-ling,WU Chun-cheng,LIANG Hui-qing,et al.Serum Marker Chitinase 3-like Protein 1 in the Evaluation of Liver Fibrosis[J].Journal of Medical Information,2021,34(21):32.[doi:10.3969/j.issn.1006-1959.2021.10.009]
[5]郭月欢,甘惠中.幽门螺旋杆菌感染与非酒精性脂肪肝的相关性研究[J].医学信息,2022,35(08):89.[doi:10.3969/j.issn.1006-1959.2022.08.021]
　GUO Yue-huan,GAN Hui-zhong.Correlation Between Helicobacter Pylori Infection and Nonalcoholic Fatty Liver Disease[J].Journal of Medical Information,2022,35(21):89.[doi:10.3969/j.issn.1006-1959.2022.08.021]
[6]陈 超,陈冯梅.血清尿酸/肌酐比值与老年人非酒精性脂肪肝的相关性研究[J].医学信息,2023,36(19):71.[doi:10.3969/j.issn.1006-1959.2023.19.014]
　CHEN Chao,CHEN Feng-mei.Correlation Between Serum Uric Acid/Creatinine Ratio and Nonalcoholic Fatty Liver Disease in the Elderly[J].Journal of Medical Information,2023,36(21):71.[doi:10.3969/j.issn.1006-1959.2023.19.014]
[7]王 晶,曹名波.非酒精性脂肪肝相关基因多态性的研究进展[J].医学信息,2023,36(24):183.[doi:10.3969/j.issn.1006-1959.2023.24.043]
　WANG Jing,CAO Ming-bo.Research Progress on Gene Polymorphisms Related to Non-alcoholic Fatty Liver Disease[J].Journal of Medical Information,2023,36(21):183.[doi:10.3969/j.issn.1006-1959.2023.24.043]

更新日期/Last Update: 1900-01-01